Nov 8 (Reuters) - Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period since the administration of the drug in a late-stage trial. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Regeneron's antibody therapy shows long-term protection against COVID-19
![Reuters logo](/images/reuters.jpg)